Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRAF and MEK Targeted Therapies in Pediatric Central Nervous System Tumors

31 Aug 2022

Abstract excerpt

BRAF is a component of the MAPK and PI3K/AKT/mTOR pathways that play a crucial role in cellular proliferation, differentiation, migration, and angiogenesis. Pediatric central nervous system tumors very often show mutations of the MAPK pathway, as demonstrated by next-generation sequencing (NGS), which now has an increasing role in cancer diagnostics. The MAPK mutated pathway in pediatric CNS tumors is the target...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Glioma Diagnosis and Treatment
Share to Cancer Mechanisms and Therapy
Share to Melanoma and MAPK Pathways

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36077798
DOI: 10.3390/cancers14174264

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 20 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRAF and MEK Targeted Therapies in Pediatric Central Nervous System TumorsPMID 36077798Read ↗

Current Understanding of BRAF Alterations in Diagnosis, Prognosis, and Therapeutic Targeting in Pediatric Low-Grade GliomasSemantic proximity Read ↗

Optimizing preclinical pediatric low-grade glioma models for meaningful clinical translation.Semantic proximity Read ↗

Molecular Heterogeneity in BRAF-Mutant Gliomas: Diagnostic, Prognostic, and Therapeutic ImplicationsSemantic proximity Read ↗

Clinicopathological analysis of BRAF and non-BRAF MAPK pathway-altered gliomas in paediatric and adult patients: a single-institution study of 40 patientsSemantic proximity Read ↗

Pediatric low-grade glioma in the era of molecular diagnostics.Semantic proximity Read ↗

Resistance mechanisms in BRAFV600E paediatric high-grade glioma and current therapeutic approachesSemantic proximity Read ↗

Integrated Molecular and Clinical Analysis of 1,000 Pediatric Low-Grade Gliomas.Semantic proximity Read ↗

Paediatric high and low grade glioma: the impact of tumour biology on current and future therapy.Semantic proximity Read ↗

Beyond Base Camp: Promise and Pitfalls of PI3K/mTOR Inhibition in Pediatric High- Grade GliomasSemantic proximity Read ↗

Clinical Characterization of FGFR-Altered Pediatric Low-Grade Gliomas.Semantic proximity Read ↗

The first-in-class ERK inhibitor ulixertinib shows promising activity in mitogen-activated protein kinase (MAPK)-driven pediatric low-grade glioma models.Semantic proximity Read ↗

Improving Diagnostic and Therapeutic Outcomes in Pediatric Brain Tumors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.